Abstract Number: 2421 • 2015 ACR/ARHP Annual Meeting
Experience with Adalimumab for Treatment of 568 Juvenile Idiopathic Arthritis Patients in the German JIA Biologics Register
Background/Purpose: Adalimumab (ADA) has become a valuable option for treatment of juvenile idiopathic arthritis (JIA), which significantly improves the outcome of patients. The aim of…Abstract Number: 2422 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a debilitating form of arthritis associated with systemic symptoms such as anemia, rash, leukocytosis, elevated erythrocyte sedimentation rate…Abstract Number: 2423 • 2015 ACR/ARHP Annual Meeting
An Open-Label Extension Study to Assess the Long-Term Safety and Clinical Benefit of Etanercept on Children and Adolescents with Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, or Psoriatic Arthritis: A 4-Year Update
Background/Purpose: A Phase 3b, open-label, multicenter study (CLIPPER; NCT00962741) demonstrated the efficacy of etanercept (ETN) in subjects with the extended oligoarticular (eo), enthesitis-related (ERA), and…Abstract Number: 2424 • 2015 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
Background/Purpose: Macrophage activation syndrome (MAS), a potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA), was reported as an adverse event in both canakinumab and…Abstract Number: 2425 • 2015 ACR/ARHP Annual Meeting
Safety of Tocilizumab in Young Adults with Juvenile Idiopathic Arthritis (JIA)
Background/Purpose: Tocilizumab was recently approved for the treatment of systemic JIA (sJIA) and polyarticular JIA (pJIA). Published data on the tolerability of tocilizumab in patients…Abstract Number: 2426 • 2015 ACR/ARHP Annual Meeting
Medication Taper and Risk of Relapse in Pediatric Uveitis
Background/Purpose: Pediatric uveitis can be vision-threatening. Treatment typically consists of ocular steroids, methotrexate, and anti-tumor necrosis factor (TNF) agents. Optimal duration of treatment and risk…Abstract Number: L25 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Subcutaneous Tabalumab in Patients with Systemic Lupus Erythematosus (SLE): Results from 2 Phase 3, 52-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trials
Background/Purpose: B-cell Activating Factor (BAFF) is a key regulator of B-cell development, survival, and activation. Tabalumab is a human IgG4 monoclonal antibody, administered subcutaneously, that binds…Abstract Number: 3017 • 2014 ACR/ARHP Annual Meeting
Program Evaluation of ‘the Joint Clinic’: An Innovative Clinical Service for Patients with Hip or Knee Osteoarthritis
Background/Purpose: In socialized healthcare systems with free public access to healthcare, there are circumstances wherein patients referred by general medical practitioners (GPs) for specialist physician…Abstract Number: 3018 • 2014 ACR/ARHP Annual Meeting
Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis
Background/Purpose Self-report questionnaires and performance-based tests correlate moderately in measuring activity limitations, indicating that they measure different aspects. Self-reports measure mainly how patients think they…Abstract Number: 2997 • 2014 ACR/ARHP Annual Meeting
Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients
Background/Purpose : Knowledge of mortality risk and predictors is important in systemic sclerosis (SSc) patient care and clinical trial design. There is no validated 5-year…Abstract Number: 2998 • 2014 ACR/ARHP Annual Meeting
Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study
Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high…Abstract Number: 2999 • 2014 ACR/ARHP Annual Meeting
Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis—the Combined Response Index in Systemic Sclerosis
Background/Purpose: Diffuse systemic sclerosis (dcSSc) is a multisystem disease that involves skin and internal organs. Our objective was to develop a composite response index in…Abstract Number: 3000 • 2014 ACR/ARHP Annual Meeting
Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity
Background/Purpose: Identifying systemic sclerosis (SSc) subsets that predict mortality and morbidity could provide useful prognostic information. We undertook this study to compare the predictive ability…Abstract Number: 3001 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis
Background/Purpose: Interleukin 6 (IL-6) is a pleiotropic cytokine involved in inflammatory and autoimmune processes. Preliminary data have suggested that IL-6 might contribute to systemic sclerosis…Abstract Number: 3002 • 2014 ACR/ARHP Annual Meeting
Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis
Background/Purpose Systemic sclerosis (SSc) is an irreversible fibrotic disorder with interstitial lung disease (ILD) being a major complication and leading cause of mortality. African American…
ACR Meeting Abstracts